Anzeige
Mehr »
Mittwoch, 18.03.2026 - Börsentäglich über 12.000 News
Geopolitik treibt Kurse: Wird dieses "unsichtbare" Metall zum nächsten Milliarden-Play?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
259 Leser
Artikel bewerten:
(1)

Cenevo's Labguru Drives Digital Lab Transformation for Pace Life Sciences

LONDON and MINNEAPOLIS, March 18, 2026 /PRNewswire/ -- Cenevo's Labguru platform is delivering a comprehensive solution to centralize documentation processes at Pace Life Sciences, a U.S.-based contract development and manufacturing organization (CDMO) and full-service good manufacturing practice (GMP) analytical laboratory service provider.

Labguru is an all-in-one cloud-based laboratory data management research-to-production platform, combining an electronic lab notebook (ELN), inventory management, registration, laboratory information management system (LIMS) and AI-based informatics tools. Scientists utilize Labguru to plan, document, track, streamline, automate and share their scientific research.

Labguru's flexible, tailored solution for Pace Life Sciences incorporates key modules, including an ELN, inventory, equipment, storage, workflow editor and dashboards to enable their team to streamline workflows, enhance compliance, and scale efficiently across operations.

"We needed a system that will grow with us and accommodate our unique workflows and better serve our clients." said Cynthia Hansen, IT Program Director at Pace Life Sciences. "Labguru makes that possible, and the team is collaborative and committed to finding solutions that meet those needs. They don't just provide a tool; they partner with us to improve our workflows."

The addition of these digital workflows eliminates manual data entry, improves inventory visibility, and give scientists more time to focus on critical work and client deadlines. Integrated instruments, standardized data capture, and secure remote access strengthen data integrity, compliance and collaboration across Pace while eliminating paper-based processes.

Adam Michel, Senior ELN Specialist at Pace Life Sciences, added: "Labguru is highly flexible and configurable, allowing us to build a system tailored specifically to our workflows and processes."

Pace plans to expand its use of Labguru across its network to support ongoing growth. The platform has already been implemented across four GMP analytical services laboratories, with additional rollouts underway.

The close collaboration between Pace and Labguru ensures consistent alignment with operational and regulatory requirements. "We are proud to support Pace in scaling its laboratory and manufacturing services with a flexible, future-ready AI-enabled platform," said Gal Hasse, VP Product Labguru at Cenevo.

About Pace Life Sciences

Pace Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. Our network of CDMO sites consists of GMP analytical testing laboratories and manufacturing support service centers. Our experienced, highly trained industry experts and our investment in state-of-the-art development and manufacturing facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the best and most reliable services with positive customer experiences across all channels of our business. https://www.pacelabs.com/life-sciences/

About Cenevo

Cenevo specializes in lab management systems, automation, orchestration, data management and AI technology for life sciences. We are trusted by scientists, companies, and research institutions worldwide, from small biotech to global pharma, with over 950 customers - including 8 out of the top 10 pharmas - and 45,000+ scientist users worldwide. Our team of more than 200 provides customers with global support from our offices in the UK, US, Israel, and Poland.

We enable connected labs that are automated, data-centric and AI enabled. Cenevo brings together Mosaic's sample-centric lab operations with Labguru's experimental-centric inventory, registration, ELN, and LIMS technology. We empower scientists to do more science to deliver faster reproducible results at a lower cost. www.cenevo.com

Logo: https://mma.prnewswire.com/media/2741003/Cenevo_Logo.jpg

Media Contact
Amy Kenigsberg
K2 Global Communications
amy@k2-gc.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/cenevos-labguru-drives-digital-lab-transformation-for-pace-life-sciences-302717222.html

© 2026 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.